Search

everythinglearnresearchcommunity

for

Search:↓

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Early recognition of symptoms is crucial for treating IPEX syndrome with a stem cell transplant.

DAB labeling effectively identifies collagen type III and PDGFR in horse skin, but may show false positives.

OR-101 shows promise for treating alopecia areata by improving hair growth.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

IGF2BP3 and other m6A-related genes are linked to keloid formation and could be potential treatment targets.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

High-dose IV iron is safe and effective for treating anaemia in IBD patients.

Retinoic acid, glucocorticoids, and IGF1 increase IGFBP-3 production in human dermal papilla cells, affecting hair growth.

Upadacitinib effectively treats pyoderma gangrenosum.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

Janus kinase inhibitors may help treat lichen planopilaris.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Icariin can regulate macrophages and may help treat inflammation, cancer, bone disorders, and fibrotic diseases.